NCT03383822View on ClinicalTrials.gov

Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

December 1, 2017

Conditions
Insulin Resistance
Interventions
DRUG

Intranasal insulin

Humalog lispro 40 IU intranasally

DRUG

Intranasal placebo

Diluent intranasally

Trial Locations (1)

M5G 1L7

Tornto General Hospital, UHN, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance | Biotech Hunter | Biotech Hunter